Ono Pharmaceutical Co. Ltd. ADR (ON40)

Overview

Ono Pharmaceutical Co., Ltd., is a global pharmaceutical company with a significant presence in the health care sector through its production, purchasing, and sales of pharmaceuticals and diagnostic reagents. With a broad portfolio that spans from cancer treatments to remedies for chronic conditions such as diabetes and heart failure, Ono Pharmaceutical stands out for its innovative approach to healthcare solutions. The company is actively involved in advanced research and collaboration efforts with renowned institutions and companies to discover and develop novel therapeutic drugs and treatments. Founded over 300 years ago in 1717, Ono Pharmaceutical has its headquarters in Osaka, Japan, showcasing a long-standing tradition in the pharmaceutical industry combined with cutting-edge research and development activities.

Products and Services

• Opdivo Intravenous Infusion and Kyprolis Intravenous Injection - These products are designed for the treatment of malignant tumors, offering advanced options for cancer care.
• Emend capsules/Proemend intravenous injections - Aimed at preventing chemotherapy-induced nausea and vomiting, enhancing patient comfort during cancer treatment.
• Demser capsules - Used for alleviating symptoms in patients suffering from pheochromocytoma, a type of tumor affecting the adrenal glands.
• Mektovi, Velexbru, and Braftovi capsules - These medications target malignant tumors, forming a crucial part of Ono Pharmaceutical's oncology portfolio.
• ADLUMIZ tablets - Specifically developed for treating cancer cachexia, which involves weight loss and muscle depletion in cancer patients.
• Glactiv tablets and Forxiga tablets - Offer treatments for type 2 diabetes, highlighting Ono Pharmaceutical's commitment to addressing this widespread chronic condition.
• Onoact Intravenous Infusion - This medication is prescribed for tachyarrhythmia, an irregular heartbeat condition.
• Opalmon tablets - Aimed at treating peripheral circulatory disorder, it helps in improving blood flow.
• Coralan - Used for managing chronic heart failure, Coralan represents the company's interest in cardiology.
• Orencia injections - These are designated for the treatment of rheumatoid arthritis, providing relief from the autoimmune disease's symptoms.
• Rivastach patches - Developed for Alzheimer's disease, these patches address the cognitive decline associated with the condition.
• Ongentys tablets - Aimed at patients with Parkinson's disease, these tablets focus on improving life quality by managing symptoms.
• Parsabiv, Staybla tablets, Onon capsules and Dry Syrups - Catering to a range of conditions from dialysis support to treating overactive bladder, asthma, and allergic rhinitis.
• JOYCLU intra-articular injection and Recalbon tablets - These offer treatments for joint function improvement and osteoporosis, respectively, further showcasing Ono Pharmaceutical's diverse healthcare solutions.